Skip to content

Group News

Quality of S-26 in South Africa Guaranteed

Aug 30, 2009

Johannesburg: Aspen Nutritionals, manufacturer of S-26 and other infant milk formulations (IMFs), confirms that all IMFs manufactured and marketed by Aspen Nutritionals are safe for infant consumption. This statement is being issued in response to a media report concerning the Tanzanian Food and Drug Administration’s withdrawal notification of a consignment of S-26, which, until proven…

Read More >>

Official statement regarding the alleged purchase transactions entered into between Aspen and Frankel Chemicals

Jun 17, 2009

OFFICIAL STATEMENT REGARDING THE ALLEGED PURCHASE TRANSACTIONS ENTERED INTO BETWEEN ASPEN AND FRANKEL CHEMICALS FOR THE PURCHASE BY ASPEN FROM FRANKEL CHEMICALS OF RAW MATERIALS FOR THE MANUFACTURE OF ANTI-RETROVIALS. ASPEN PHARMACARE HOLDINGS LIMITED AND ITS AFFILIATES (“Aspen”) AND FRANKEL CHEMICALS (“Frankel”) It has come to the attention of Aspen that information allegedly pertaining to…

Read More >>

Aspen and GSK agree on Strategic Deals

May 12, 2009

Press Conference Presentation <Click to download> SENS Announcement <Click to download> The Transactions comprise: The acquisition of the rights to distribute GSK products in South Africa by Aspen’s wholly owned subsidiary, Pharmacare Limited (“the SA Component”); The formation of a collaboration arrangement in relation to the marketing and selling of prescription pharmaceutical products in sub-Saharan…

Read More >>

Aspen’s offshore operations drive an impressive 91% revenue increase

Mar 5, 2009

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded strong revenue growth for the six months ended 31 December 2008. The positive returns were stimulated by Aspen’s recently expanded international operations. The existing businesses in South Africa and Australia have once again recorded sustained growth. Revenue increased by 91 percent to R4…

Read More >>

Trading Update

Feb 12, 2009

Aspen shareholders are hereby advised that earnings per share, for the 6 months ended 31 December 2008, are forecast to exceed those reported in the comparative period ended 31 December 2007, by 45-60%. Headline earnings per share are forecast to exceed those of the comparative period by 65-80%. As anticipated, a strong contribution from Aspen’s…

Read More >>

Aspen Appoints Noel Guliwe as Chief Executive in South Africa

Jan 12, 2009

JOHANNESBURG: Aspen Holdings is pleased to announce the appointment by its principal South African subsidiary of Noel Guliwe as Chief Executive: South Africa with effect from January 12, 2009. “The rapid globalization of the Aspen Group has necessitated increased attention from Aspen’s senior executives. Consequently, this appointment has been made to ensure that the local…

Read More >>

Aspen Matrix Release

Oct 9, 2008

Aspen Pharmacare Holdings Limited (“Aspen”) and Matrix Laboratories Limited (“Matrix”) of the Republic of India, would like to announce the divestment of the existing joint ventures relating to the two chemical-manufacturing entities, Fine Chemicals Corporation (Proprietary) Limited (“FCC”) in Cape Town, South Africa and Astrix Laboratories (“Astrix”) Limited in Hyderabad, India. Aspen will acquire 50%…

Read More >>

Aspen establishes its international platform for future growth

Sep 16, 2008

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer, is pleased to announce positive results for the year ended 30 June 2008. The Group delivered sustained growth from its existing bases in South Africa, Australia and Asia. A series of significant transactions were concluded to expand the Group’s footprint into Latin America,…

Read More >>

Revision of Terms of Aspen`s Investment in Strides` Latin American Operations

Sep 16, 2008

Further to the announcement made on 20 November 2007, Aspen is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“Global”) has agreed revised terms with Strides Arcolab Limited (“Strides”), a pharmaceutical company registered in the Republic of India, in respect of certain aspects of Global’s acquisition of an interest in Strides’ Latin…

Read More >>

Aspen Businesses in Licensing Deal With GSK

Jul 22, 2008

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited (Apn) has announced today that it has entered into licensing and supply agreements with leading multinational pharmaceutical corporation, GlaxoSmithKline (“GSK”). In terms of the agreements Aspen will license intellectual property and supply finished dosage form pharmaceuticals to GSK through Aspen Group companies including Onco Therapies Limited (“OTL”),…

Read More >>

MEDIA ENQUIRIES

Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com

Scroll To Top